Scientific Method be damned, medical journals have an economic incentive for publishing papers with postive outcomes. When a drug study shows positive outcomes, pharmaceutical companies buy reprints of it in bulk to distribute it to prescribers.
Those purchases can add up to over $2 million. For journals like The Lancet ($40 annual revenue) and NEJM ($100 million/yr.), that’s huge. 41 percent of The Lancet’s 2021 income came from reprints. When it comes to drug studies, Big Phama’s thumb is firmly on the scale.
More:
Scientific journals are incentivized to publish positive drug studies,” Annalisa Merelli, Quartz
Related:
“Why Most Published Research Findings Are False,” John P. A. Ioannidis, PLOS Medicine
___________________
Short link: https://wp.me/p6sb6-yLt
Image by Mike Licht. Download a copy here. Creative Commons license; credit Mike Licht, NotionsCapital.com
Comments are welcome if they are on-topic, substantive, concise, and not boring or obscene. Comments may be edited for clarity and length.
Tags: Big Pharma, drug industry, drug research, drug studies, medical publications, NEJM, pharmaceutical industry, Pharmaceutical Money, pharmaceuticals, prescription drugs, Quartz, science, scientific method, scientific publications, The Lancet
NotionsCapital 
Leave a Reply